5.43
price up icon6.26%   0.32
after-market Handel nachbörslich: 5.45 0.02 +0.37%
loading
Schlusskurs vom Vortag:
$5.11
Offen:
$5.13
24-Stunden-Volumen:
1.39M
Relative Volume:
1.06
Marktkapitalisierung:
$749.25M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.3852
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+4.62%
1M Leistung:
+7.10%
6M Leistung:
-25.31%
1J Leistung:
-38.64%
1-Tages-Spanne:
Value
$5.015
$5.44
1-Wochen-Bereich:
Value
$4.91
$5.44
52-Wochen-Spanne:
Value
$4.32
$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
Firmenname
Vir Biotechnology Inc
Name
Telefon
415-906-4324
Name
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Name
Mitarbeiter
408
Name
Twitter
@Vir_Biotech
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
VIR's Discussions on Twitter

Vergleichen Sie VIR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VIR
Vir Biotechnology Inc
5.43 749.25M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-01-29 Herabstufung JP Morgan Overweight → Neutral
2023-09-08 Herabstufung BofA Securities Buy → Neutral
2023-03-06 Hochstufung JP Morgan Neutral → Overweight
2023-02-21 Hochstufung Goldman Neutral → Buy
2023-01-27 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-09-14 Eingeleitet SVB Leerink Outperform
2022-09-09 Eingeleitet Morgan Stanley Underweight
2022-03-03 Hochstufung Robert W. Baird Underperform → Neutral
2021-12-21 Herabstufung Robert W. Baird Neutral → Underperform
2021-10-25 Hochstufung JP Morgan Underweight → Neutral
2021-09-22 Herabstufung Goldman Buy → Neutral
2021-06-04 Fortgesetzt Robert W. Baird Neutral
2021-01-27 Herabstufung JP Morgan Neutral → Underweight
2021-01-20 Bestätigt H.C. Wainwright Buy
2020-10-05 Eingeleitet BofA Securities Buy
2020-09-14 Hochstufung Goldman Neutral → Buy
2020-09-11 Hochstufung JP Morgan Underweight → Neutral
2020-08-20 Eingeleitet Needham Buy
2020-03-19 Herabstufung JP Morgan Neutral → Underweight
2020-03-13 Herabstufung Goldman Buy → Neutral
2020-02-27 Herabstufung Robert W. Baird Neutral → Underperform
2020-02-04 Herabstufung JP Morgan Overweight → Neutral
2019-11-14 Eingeleitet Robert W. Baird Neutral
2019-11-05 Eingeleitet Barclays Overweight
2019-11-05 Eingeleitet Cowen Outperform
2019-11-05 Eingeleitet Goldman Buy
2019-11-05 Eingeleitet JP Morgan Overweight
Alle ansehen

Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten

pulisher
Jun 17, 2025

Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 10, 2025

Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener

Jun 10, 2025
pulisher
Jun 05, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 03, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia

Jun 03, 2025
pulisher
Jun 02, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
May 29, 2025

Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks

May 29, 2025
pulisher
May 29, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace

May 29, 2025
pulisher
May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com

May 27, 2025
pulisher
May 22, 2025

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

May 22, 2025
pulisher
May 22, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace

May 21, 2025
pulisher
May 20, 2025

Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

May 20, 2025
pulisher
May 15, 2025

How To Trade (VIR) - news.stocktradersdaily.com

May 15, 2025
pulisher
May 15, 2025

Vir announces 24-week post-end of treatment data for Hep B therapy - MSN

May 15, 2025
pulisher
May 14, 2025

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN

May 14, 2025
pulisher
May 12, 2025

Vir Biotechnology (VIR) Maintains 'Buy' Rating as Price Target A - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference - BioSpace

May 12, 2025
pulisher
May 12, 2025

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

May 12, 2025
pulisher
May 12, 2025

Vir Biotechnology Announces Results of Its Potential Hepatitis B Cure Combination Therapy - ContagionLive

May 12, 2025
pulisher
May 11, 2025

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

May 11, 2025
pulisher
May 10, 2025

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Trea - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - BioSpace

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Tr - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus

May 09, 2025
pulisher
May 08, 2025

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks

May 08, 2025

Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):